AbbVie Inc.: enforcement record and regulatory exposure
AbbVie Inc. scores 70 out of 100 on the RedFlag Index™ (October 2026), ranking #3 of ten tracked companies, with 6 documented cases of which 3 remain open.
Documented record
AbbVie has paid more than $7.5 billion in tracked penalties since 2000, including Abbott-era matters.
2025: AbbVie paid Oregon $9.25 million over AndroGel marketing.
2023: AbbVie paid $2.7 million to settle Humira kickback allegations.
2022: Allergan, an AbbVie subsidiary, agreed to pay up to $2.37 billion in a nationwide opioid settlement.
2020: AbbVie paid California $24 million over Humira marketing allegations.
RegulationWatch coverage
- Opioid Litigation
AbbVie bought Allergan and inherited an opioid bill of up to $2.37 billion.
Allergan had sold its generic opioid business years earlier. The liability stayed, and the settlement carries no admission.
- Medicare Negotiation
Supreme Court declines drugmaker appeals against Medicare drug price negotiation program
The US Supreme Court rejected appeals from pharmaceutical companies challenging the Medicare drug price negotiation program created by the 2022 Inflation Reduction Act. The justices left in place Third Circuit rulings dismissing the manufacturers' claims without comment.
- Drug Pricing
Federal judge rejects Merck's constitutional challenge to Medicare drug price negotiation
Judge Colleen Kollar-Kotelly of the US District Court for the District of Columbia rejected Merck's First and Fifth Amendment challenge to the Inflation Reduction Act's Medicare drug price negotiation programme. Merck filed the first industry challenge to the programme in June 2023.
